Home
>
US Stocks
>
PROQR THERAPEUTICS NV

PROQR THERAPEUTICS NV (PRQR)

$1.715

+0.05

(+2.69%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on PROQR THERAPEUTICS NV

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 1.23M → 655.0K (in $), with an average decrease of 14.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -24.39M → -7.99M (in $), with an average increase of 78.4% per quarter

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 27.7% return, outperforming this stock by 97.1%

Performance

  • $1.65
    $1.73
    $1.72
    downward going graph

    4.07%

    Downside

    Day's Volatility :4.62%

    Upside

    0.58%

    downward going graph
  • $0.59
    $3.85
    $1.72
    downward going graph

    65.52%

    Downside

    52 Weeks Volatility :84.59%

    Upside

    55.32%

    downward going graph

Returns

PeriodPROQR THERAPEUTICS NVSector (Health Care)Index (Russel 2000)
3 Months
-41.86%
0.3%
-6.7%
6 Months
36.11%
-6.3%
-3.4%
1 Year
159.85%
-4.8%
-6.3%
3 Years
-69.37%
25.3%
26.3%

Highlights

Market Capitalization
133.5M
Book Value
$0.73
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.8
PEG Ratio
0.0
Wall Street Target Price
3.97
Profit Margin
0.0%
Operating Margin TTM
-1336.95%
Return On Assets TTM
-20.48%
Return On Equity TTM
-75.04%
Revenue TTM
4.3M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-47.8%
Gross Profit TTM
4.8M
EBITDA
-56.3M
Diluted Eps TTM
-0.8
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.31
EPS Estimate Next Year
-0.48
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for PROQR THERAPEUTICS NV(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
4
4
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 131.49%

Current $1.72
Target $3.97

Technicals Summary

Sell

Neutral

Buy

PROQR THERAPEUTICS NV is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
-21.33%
36.11%
159.85%
-69.37%
-70.68%
Moderna, Inc.
Moderna, Inc.
-5.0%
-28.02%
-13.14%
127.3%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.64%
-2.29%
8.99%
25.3%
144.36%
Seagen, Inc.
Seagen, Inc.
-3.25%
59.62%
42.61%
27.67%
248.38%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.15%
4.66%
22.83%
18.97%
112.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
NA
NA
0.0
-0.31
-0.75
-0.2
0.0
0.73
Moderna, Inc.
Moderna, Inc.
11.28
11.28
0.0
-1.96
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.02
20.02
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.02
27.02
0.41
14.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
Buy
$133.5M
-70.68%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.2B
578.71%
11.28
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
144.36%
20.02
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
248.38%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.7B
112.57%
27.02
35.4%

Institutional Holdings

  • Privium Fund Management B.V.

    6.61%

  • Adage Capital Partners Gp LLC

    4.49%

  • M28 Capital Management LP

    2.36%

  • Opaleye Management Inc

    1.81%

  • Macquarie Group Ltd

    0.77%

  • Ikarian Capital, LLC

    0.52%

Corporate Announcements

  • PROQR THERAPEUTICS NV Earnings

    PROQR THERAPEUTICS NV’s price-to-earnings ratio stands at None

    Read More

Company Information

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on its unique proprietary RNA repair platform technologies, the Company is growing its pipeline with patients and loved ones in mind.

Organization
PROQR THERAPEUTICS NV
Employees
130
CEO
Dr. Domenico Valerio Ph.D.
Industry
Health Technology

Discover More

FAQs